Vanc Pharmaceuticals Inc., a pharmaceutical company focused on the Canadian generic drug and over-the-counter (OTC) markets, announces that Health Canada has approved Cortivera-H, a premium topical product for minor skin irritations.
Cortivera-H has been approved for pharma care reimbursement program in the BC formulary and is in the process to get listed in other provincial formularies.
Cortivera-H, a made in Canada product, contains 1% hydrocortisone cream for the treatment of minor skin irritations associated with redness, itching, dryness, and scaling; rashes, eczema, insect bites, poison ivy, poison oak, poison sumac, contact Seborrheic dermatitis, psoriasis, external genital feminine itching, and anal itching due to hemorrhoids.
“We are excited to be launching a broad spectrum product, Cortivera-H, across Canada and are pleased with the early feedback from our customers and volume of initial orders,” said Arun Nayyar, CEO of Vanc. “Our sales force has been detailing physicians and pharmacies in order to drive awareness and orders of the product.”
In order to market the company’s portfolio of generic molecules and the growing OTC portfolio the company has now hired sales staff in Ontario, Alberta, and British Columbia bringing the total to 6 fulltime sales people. “As we introduce additional new high margin OTC products to the market over the next several months we will continue to add sales people in each of our focus markets,” said Nayyar.
Over the next two quarters the company expects to launch additional OTC products that represent the top selling product categories in Canada.
Follow us on Twitter and Facebook for updates on the latest pharmaceutical and biopharmaceutical manufacturing news!
Filed Under: Drug Discovery
